Willem Hazenberg

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands.

Piculet Biosciences BV develops and markets oligonucleotide binding moieties for pharmaceutical applications. The firm’s oligonucleotide synthesis system combines pace derived hardware engineering with biochemistry and nucleotide photo-deprotection technology into an integrated bench-top instrument for oligonucleotide production. The company was founded in December 2004 and is headquartered in Leiden, the Netherlands.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.

Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands.